AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT05035498
Drug: Phenylephrine
RxNorm normalized name: Phenylephrine
DrugBank: Phenylephrine (DB00388)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A maintenance dose of phenylephrine (0.625 μg/kg/min) infusion simultaneous with subarachnoid block
Trial: NCT04629729
Drug: Fludarabine
RxNorm normalized name: Fludarabine
DrugBank: Fludarabine (DB01073)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lympho-conditioning agent
Trial: NCT04629729
Drug: IL-2
RxNorm normalized name: IL-2
DrugBank: Human interleukin-2 (DB14865)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Biologic response modifier
Trial: NCT04629729
Drug: Bendamustine
RxNorm normalized name: Bendamustine
DrugBank: Bendamustine (DB06769)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Lympho-conditioning agent
Trial: NCT05465135
Drug: Dihydroartemisinin
RxNorm normalized name: Dihydroartemisinin
DrugBank: Artenimol (DB11638)
FDA approved: no
EMA approved: yes
PMDA approved: no
Description: Dihydroartemisinin 40mg three times a day for 12 consecutive weeks.
Trial: NCT05182164
Drug: Association of pembrolizumab + cabozantinib
DrugBank: Cabozantinib (DB08875)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: A treatment cycle consists of 3 weeks. Pembrolizumab will be administered intraveinously on day 1 every 3 weeks (200 mg).~Cabozantinib will be administered per os, once daily (40 mg), and given on a continuous basis.
Trial: NCT04814537
Drug: Bupivacaine Hydrochloride
RxNorm normalized name: Bupivacaine Hydrochloride
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Local Anesthetic Agent
Trial: NCT05453799
Drug: Vudalimab
RxNorm normalized name: Vudalimab
DrugBank: Vudalimab (DB18833)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IV
Trial: NCT05356793
Drug: SCH-1
RxNorm normalized name: SCH-58500
DrugBank: SCH-58500 (DB17416)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Novel anti-infective eyedrop
Trial: NCT05619848
Drug: Rocuronium Bromide
RxNorm normalized name: Rocuronium Bromide
DrugBank: Rocuronium (DB00728)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg rocuronium was injected intravenously, and rocuronium was pumped during operation to maintain deep muscle relaxation
Trial: NCT05290220
Drug: HLX07
RxNorm normalized name: Lanraplenib
DrugBank: Lanraplenib (DB14770)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1500 mg
Trial: NCT05290220
Drug: HLX10
RxNorm normalized name: Immunoglobulin g4 (228-proline), anti-(human programmed cell death protein 1) (human-mus musculus monoclonal hlx10 .gamma.4-chain), disulfide with human-mus musculus monoclonal hlx10 .kappa.-chain, dimer
DrugBank: Serplulimab (DB17451)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg
Trial: NCT05290220
Drug: HLX04
RxNorm normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 15mg/kg
Trial: NCT05290220
Drug: lenvatinib
RxNorm normalized name: Lenvatinib
DrugBank: Lenvatinib (DB09078)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 12 mg (BW≥60 kg) or 8 mg (BW \<60 kg)
Trial: NCT05596981
Drug: Sorafenib
RxNorm normalized name: Sorafenib
DrugBank: Sorafenib (DB00398)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The initial dose of sorafenib is 400 mg orally twice daily and is adjusted in case of suspected toxicity or resistance (dose range, 200-800 mg daily).
Trial: NCT05559814
Drug: Intraluminal peppermint oil
RxNorm normalized name: Peppermint Oil
DrugBank: Peppermint (DB10984)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraluminal flushing of peppermint oil solution through the scope channel during the scope withdrawal
Trial: NCT04515836
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Olaparib is a chemotherapy drug (packaged as a pill) that can be taken by mouth, twice daily.
Trial: NCT05902728
Drug: Itraconazole 200 mg
RxNorm normalized name: itraconazole 200 MG
DrugBank: Itraconazole (DB01167)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 200 mg
Trial: NCT05902728
Drug: Rifampicin
RxNorm normalized name: Rifampicin
DrugBank: Rifampin (DB01045)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 600mg
Trial: NCT05076422
Drug: BI 3006337
RxNorm normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BI 3006337
Trial: NCT06008379
Drug: 7MW3711 for injection
RxNorm normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 7MW3711, Q3W, 3 weeks a cycle
Trial: NCT06008379
Drug: 7MW3711 for injection
RxNorm normalized name: 7MW3711
DrugBank: 7MW3711 (DB19298)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV administration of 7MW3711, the dosage regimen including dosage and dosing frequency for cohort expansion is conformed on basis of the data in part 1
Trial: NCT05158062
Drug: olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: olaparib 300 mg twice daily (BID) during maintenance period
Trial: NCT05158062
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: carboplatin AUC=5 or 6 Q3W during treatment period
Trial: NCT05158062
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: paclitaxel 175 mg/m2 Q3W during treatment period
Trial: NCT05158062
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: docetaxel 60 \~ 70 mg/m2 Q3W during treatment period
Trial: NCT05347069
Drug: Aspirin
RxNorm normalized name: Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Aspirin 100 mg/day
Trial: NCT04632199
Drug: 111In-IPN01087 Low dose
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered once via slow intravenous injection.
Trial: NCT04632199
Drug: 111In-IPN01087 High dose
RxNorm normalized name: high-density polyethylene
DrugBank: Poly(lactic acid) (DB15037)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered once via slow intravenous injection.
Trial: NCT00014742
Drug: collagenase
RxNorm normalized name: Collagenase
DrugBank: Collagenase clostridium histolyticum (DB00048)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT06528314
Drug: Efruxifermin
RxNorm normalized name: Efruxifermin
DrugBank: Efruxifermin (DB19012)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by subcutaneous injection
Trial: NCT06670196
Drug: Osimertinib
RxNorm normalized name: Osimertinib
DrugBank: Osimertinib (DB09330)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 80mg, QD
Trial: NCT05347485
Drug: Cilta-cel
RxNorm normalized name: ciltacabtagene autoleucel
DrugBank: Ciltacabtagene autoleucel (DB16738)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cilta-cel will be administered as an IV infusion.
Trial: NCT04880811
Drug: Afatinib
RxNorm normalized name: Afatinib
DrugBank: Afatinib (DB08916)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Afatinib is orally administered at 40mg Qd of each 21 day cycle.
Trial: NCT04880811
Drug: Toripalimab
RxNorm normalized name: Toripalimab
DrugBank: Toripalimab (DB15043)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Toripalimab is given by intravenous infusion at 200mg d1 of each 21 day cycle.
Trial: NCT05449392
Drug: Neosporin
RxNorm normalized name: Neosporin
DrugBank: Gramicidin D (DB00027)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neosporin is neomycin, bacitracin and polymyxin B with formulation 3.5mg/400 units/5,000 units. The subject will self-apply a small amount (approximately 0.5 g) of the ointment topically into each nostril (intranasal) twice daily (morning and evening) for seven days. Subjects are to pinch the nose to spread the cream.
Trial: NCT04898907
Drug: Moxifloxacin Hydrochloride
RxNorm normalized name: Moxifloxacin Hydrochloride
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Arms assigned to this intervention will receive 400 mg, Oral, Fasted
Trial: NCT05732129
Drug: Fluzoparib
RxNorm normalized name: Fluzoparib
DrugBank: Fluzoparib (DB15637)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg,orally, bid (days 1-7) every 2 weeks
Trial: NCT05732129
Drug: Irinotecan
RxNorm normalized name: Irinotecan
DrugBank: Irinotecan (DB00762)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 30-90min continuous infusion 180mg/m2 Irinotecan on day 1, q2w
Trial: NCT01543750
Drug: 4-Aminopyridine
RxNorm normalized name: 4-aminopyridine
DrugBank: Dalfampridine (DB06637)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04919564
Drug: Furosemide in 0.9 % NaCl 100 Mg/100 mL (1 mg/mL)
RxNorm normalized name: furosemide in 0.9 % NaCl 100 mg/100 mL (1 mg/mL) INTRAVEN INTRAVENOUS SOLUTION, PIGGYBACK (ML)
DrugBank: Furosemide (DB00695)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Furosemide 2 mg/hour infusion for 12 hours since induction
Trial: NCT05629962
Drug: Bemnifosbuvir (BEM)
RxNorm normalized name: Bemnifosbuvir
DrugBank: Bemnifosbuvir (DB19050)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BEM tablets administered orally every 12 hours (twice a day) for a total of 5 days
Trial: NCT05137938
Drug: Intranasal Ketamine (IN)
DrugBank: Ketamine (DB01221)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A sterile form of ketamine will be administered intranasally twice weekly for four weeks. Dosing schedule will be determined based on patient's weight using a specialized formula. Patients will be started at the lowest dose during the first treatment session. Dose will be titrated further to therapeutic dose in the following sessions. The dose will be adjusted if patients do not tolerate full therapeutic doses. After receiving the second treatment of each week, participants will be seen by a study physician to determine dosing for the following week. Patients will be monitored by trained personnel for the full duration of the 2 hour supervision period. Vital signs and physical symptoms will be monitored consistently and measurements taken every 30 minutes. Appropriate medications will be provided to manage treatment-related side effects and any adverse events. Labetalol will be used in the management of treatment-related transient hypertension as needed.
Trial: NCT05503953
Drug: AGLS
RxNorm normalized name: Aglucosidase alfa
DrugBank: Alglucosidase alfa (DB01272)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Uptitration
Trial: NCT06526520
Drug: Exposure to progesterone or HRT medication
RxNorm normalized name: Medicated Pad or Tape
DrugBank: Progesterone (DB00396)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: to add either progesterone only in the NPP protocol or E2 and progesterone in a HRT protocol
Trial: NCT04734873
Drug: CPI-006 2 mg/kg + SOC
DrugBank: CPI-006 (DB16488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CPI-006 2 mg/kg up to a maximum dose of 200 mg plus standard of care
Trial: NCT04734873
Drug: CPI-006 1 mg/kg + SOC
DrugBank: CPI-006 (DB16488)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV CPI-006 1 mg/kg up to a maximum dose of 100 mg plus standard of care
Trial: NCT06340711
Drug: OBP-301
RxNorm normalized name: DNA (recombinant human telomerase-specific replication-competent oncolytic adenovirus 5 vector OBP-301)
DrugBank: Tipapkinogene sovacivec (DB06239)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2×10(12) viral particles per injection given intratumorally every 2 weeks for a total of 4 injections starting on Day 1 of the study
Trial: NCT06340711
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 400 mg IV given every 6 weeks starting on day 4 of the study and given for up to 2 years
Trial: NCT05357183
Drug: PEG-IFN
RxNorm normalized name: PEG-IFN alfa-2A
DrugBank: Peginterferon alfa-2a (DB00008)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PEG-IFN 180 or 135 micrograms, subcutaneously injected once a week, with a personalized treatment course of 24 weeks
Trial: NCT06334133
Drug: Cadisegliatin 800 mg QD
RxNorm normalized name: Cadisegliatin
DrugBank: Cadisegliatin (DB18886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Trial: NCT06334133
Drug: Cadisegliatin 800 mg BID
RxNorm normalized name: Cadisegliatin
DrugBank: Cadisegliatin (DB18886)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cadisegliatin is an orally bioavailable small-molecule glucokinase activator.
Trial: NCT05681728
Drug: Pembrolizumab
RxNorm normalized name: Pembrolizumab
DrugBank: Pembrolizumab (DB09037)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
Trial: NCT05681728
Drug: Paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
Trial: NCT05681728
Drug: Epirubicin
RxNorm normalized name: Epirubicin
DrugBank: Epirubicin (DB00445)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
Trial: NCT05004675
Drug: Inclisiran
RxNorm normalized name: Inclisiran
DrugBank: Inclisiran (DB14901)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 284 mg
Trial: NCT05269628
Drug: Cannabidiol (CBD)
RxNorm normalized name: cannabidiol (CBD)
DrugBank: Cannabidiol (DB09061)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Epidiolex® dose will be 0.5 mL (50 mg) twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 1 mL (100 mg) twice daily for the remainder of the treatment interval (full dose). If the full dose (100 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (50 mg twice daily).~Participants who go back to the half-dose of Cannabidiol (50 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 100 mg Cannabidiol per day. Participants who are tolerating the full-dose of medication (Cannabidiol 100 mg twice daily) will not be allowed to combine these doses into one daily dose.
Trial: NCT05269628
Drug: Tetrahydrocannabinol (THC)
RxNorm normalized name: tetrahydrocannabinol (THC)
DrugBank: Dronabinol (DB00470)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dronabinol dose will be 2.5 mg twice daily during the first seven days of active treatment (half of full anticipated dose), followed by 5 mg twice daily for the remainder of the treatment interval (full dose). If the full dose (5 mg twice daily) is not tolerated by participants, they will have the option of going down to the original half-dose (2.5 mg twice daily).~Participants who go back to the half-dose of Dronabinol (2.5 mg twice daily) also have the option to request once-per-day dosing with study drug taken at preferred time of day. Participants who request once-per-day dosing will not exceed a total daily dose 5 mg Dronabinol per day. Participants who are tolerating the full-dose of medication (Dronabinol 5 mg BID) will not be allowed to combine these doses into one daily dose.
Trial: NCT00413751
Drug: Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT05968885
Drug: Combine Mirabegron and Solifenacin.
DrugBank: Solifenacin (DB01591)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Combination pharmacotherapy
Trial: NCT06676319
Drug: Lunsekimig
RxNorm normalized name: Lunsekimig
DrugBank: Lunsekimig (DB19009)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:Solution for injection in vial-Route of administration:Subcutaneous injection
Trial: NCT06676319
Drug: Fluticasone/salmeterol
RxNorm normalized name: FLUTICASONE/SALMETEROL
DrugBank: Salmeterol (DB00938)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Trial: NCT06676319
Drug: Budesonide/formoterol
RxNorm normalized name: BUDESONIDE/FORMOTEROL
DrugBank: Formoterol (DB00983)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Pharmaceutical form:Varies and depends on pharmaceutical presentation-Route of administration:Oral Inhalation
Trial: NCT05063370
Drug: Levosimendan
RxNorm normalized name: levosimendan
DrugBank: Levosimendan (DB00922)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive Levosimendan infusion 12 hours before surgery in the ICU at a dose of 0.2 μg kg/min for the first hour and then reduced to 0.1 μg kg/ min to be continued in the operating room and then in the ICU (total infusion time of 24 hours).
Trial: NCT05911997
Drug: MTC 01
RxNorm normalized name: MTC-DOX
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Slurry to be administered via colonoscopy
Trial: NCT05911997
Drug: Fecal Microbiota Transplantation (FMT)
DrugBank: Fecal microbiota (DB17743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stool from a healthy donor is blended with salt water and made into a liquid solution rich in bacteria. This solution is sprayed into the recipient's colon during a colonoscopy
Trial: NCT05117008
Drug: Belantamab mafodotin
RxNorm normalized name: belantamab mafodotin
DrugBank: Belantamab mafodotin (DB15719)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Belantamab mafodotin will be administered IV over approximately 30 minutes at the recommended dose of 2.5 mg/kg IV over 30 minutes on day 1 of every eight-week (+/- three days) cycle for a maximum of 12 cycles. Maintenance therapy with belantamab mafodotin will continue until progressive disease (PD), death, unacceptable toxicity, withdrawal of consent or end of study (maximum of 12 cycles), whichever occurs first.
Trial: NCT04635059
Drug: Pacritinib
RxNorm normalized name: Pacritinib
DrugBank: Pacritinib (DB11697)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pacritinib is an oral drug which will be taken daily on a 28-day cycle at a dose of 200 mg twice a day (BID).
Trial: NCT06503679
Drug: Midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered orally
Trial: NCT06503679
Drug: Repaglinide
RxNorm normalized name: Repaglinide
DrugBank: Repaglinide (DB00912)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT06503679
Drug: Digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Administered orally
Trial: NCT05398445
Drug: Rocatinlimab
RxNorm normalized name: Rocatinlimab
DrugBank: Rocatinlimab (DB18809)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive Rocatinlimab subcutaneously.
Trial: NCT06212830
Drug: Gabapentin
RxNorm normalized name: Gabapentin
DrugBank: Gabapentin (DB00996)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gabapentin 200 mg twice a day, starting from the night prior to the procedure and continue 48 hours after
Trial: NCT06212830
Drug: Targin
RxNorm normalized name: Targiniq
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Targin 5 mg twice a day after the procedure for 48 hours
Trial: NCT06212830
Drug: NSAID
RxNorm normalized name: Ansaid
DrugBank: Flurbiprofen (DB00712)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Nurofen (NSAID) 200 mg twice a day after the procedure for 48 hours
Trial: NCT06212830
Drug: Paracetamol
RxNorm normalized name: Paracetamol
DrugBank: Acetaminophen (DB00316)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Paracetamol 500 mg every 4 hours during waking hours after the procedure for 48 hours
Trial: NCT05508152
Drug: Wound irrigation with amoxicillin-clavulanate in saline solution
RxNorm normalized name: amoxicillin / clavulanate
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio.~For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~In the experimental arm of the study, the circulating nurse will prepare a solution of amoxicillin-clavulanate acid (1000 mg of antibiotic in 500 mL of saline) outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with the antibiotic solution, and the soaked gauze placed on the wound for 3 minutes.
Trial: NCT05508152
Drug: Wound irrigation with a saline solution
RxNorm normalized name: Simply Saline Wound Wash
DrugBank: Benzethonium (DB11125)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Randomization will be made by means of the RedCap online program. At the arrival of the patient in the surgical area, the nursing team will be informed whether or not the patient has entered the protocol of the studio. For each included case, the perioperative nurse will access RedCap and will proceed to include and randomize the case.~Once the patient's data has been introduced, the circulating nurse will enter the intervention group in a registration database, keeping it blinded to the surgical team.~If the case belongs to the sham group, at the end of the intervention, the circulating nurse will prepare a sham solution contaning only normal saline outside the operating room. In case of open surgery, the thickness of the subcutaneous fat layer will be measured and recorded. After the closure of the aponeurosis, and before the closure of the skin, the wound will be irrigated with saline, and the soaked gauze placed on the wound for 3 minutes.
Trial: NCT06411821
Drug: Ulixertinib
RxNorm normalized name: Ulixertinib
DrugBank: Ulixertinib (DB13930)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 300 mg twice daily, for every 28-day cycle.
Trial: NCT05498272
Drug: Olaparib
RxNorm normalized name: Olaparib
DrugBank: Olaparib (DB09074)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 300 mg orally twice a day (D1-D30) for 6 Cycles (30 day Cycles)